http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
A review on solid adsorbents for carbon dioxide capture
이슬이,박수진 한국공업화학회 2015 Journal of Industrial and Engineering Chemistry Vol.23 No.-
Global warming is considered as one of the great challenges of the twenty-first century. CO2 capture and storage (CCS) technology is attracting increasing interest to reduce the ever-increasing amount of CO2 released into the atmosphere and its impact on global climate change. CO2 capture process is a core technology, and accounts for 70–80% of the total cost of CCS technologies. CO2 capture technologies are categorized as post-combustion, pre-combustion, and oxy-fuel combustion. Among these, postcombustion CO2 capture processes are regarded as being important green and economic technologies. It is very important to develop new, highly efficient adsorbents to achieve techno-economic systems for post-combustion CO2 capture. In this review, we therefore summarize dry solid adsorbents, which are divided into non-carbonaceous (e.g., zeolites, silica, metal-organic frameworks and porous polymers, alkali metal, and metal oxide carbonates) and carbonaceous materials (e.g., activated carbons, ordered porous carbons, activated carbon fibers, and graphene), with a focus on recent research.
간 이식 환자에서의 Everolimus 사용 현황 분석
이슬이,김수진,민명숙,김정미,이영미 한국병원약사회 2018 병원약사회지 Vol.35 No.2
Purpose : The Korean health insurance has covered the use of everolimus in adult patients receiving liver transplants with the concomitant use of both tacrolimus and corticosteroids since June 1st 2015. This study was conducted to analyze the use of everolimus in patients who have received a liver transplantation at the Samsung Medical Center. Methods : The secured electronic medical records of 105 patients, who took everolimus from June 1st 2015 to June 30th 2016, were retrospectively reviewed. We analyzed adherence to the recommended prescription as requried and noted and mesured the incidence of side effects. Results : Among the 105 patients, there were 103 patients (98.1%) who started everolimus treatment 4 weeks after having received their transplantation, and 62 (59.0%) started 0.5 mg/dose and 32 (30.5%) took 1 mg/dose of everolimus twice a day. The rate of maintaining the trough concentration of 3 to 8 ng/mL of everolimus was 53.0% within 1 month after the administration, 46.8% from 1 to 3 months, and 48.2% from 3 to 6 months. There were a number of patients whose serum levels were below the recommended range, but the recoded serum trough concentrations were continuously monitored and the incidence of a post-transplant rejection was low (1.9%). The blood analysis data showed more than 240 mg/dL of total cholesterol in 40 patients (38.1%) during the administration period. Conclusion : Further studies on the proper initial dose and maintenance of an adequate drug concentration ranges in the Korean population are needed. In addition, due to the increased risk of dyslipidemia after everolimus administration, the periodic monitoring of the blood lipid profiles is important and appropriate measures should be taken when necessary. Therefore, in order to contribute to effective drug use and minimize side effects, it requires a more proactive role of pharmacists in prescription monitoring and interventions with use of this therapy.